These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 26423699)

  • 1. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy.
    Abid M; Shamsi F; Azam A
    Mini Rev Med Chem; 2016; 16(10):772-86. PubMed ID: 26423699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial: Anticancer Ruthenium Complexes in Drug Discovery and Medicinal Chemistry.
    Thota S
    Mini Rev Med Chem; 2016; 16(10):771. PubMed ID: 27161007
    [No Abstract]   [Full Text] [Related]  

  • 3. Anticancer Activity and Modes of Action of (arene) ruthenium(II) Complexes Coordinated to C-, N-, and O-ligands.
    Biersack B
    Mini Rev Med Chem; 2016; 16(10):804-14. PubMed ID: 27161009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
    Lazarević T; Rilak A; Bugarčić ŽD
    Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes.
    Liu P; Jia J; Zhao Y; Wang KZ
    Mini Rev Med Chem; 2016; 16(4):272-89. PubMed ID: 26586123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy.
    Zheng K; Wu Q; Wang C; Tan W; Mei W
    Anticancer Agents Med Chem; 2017; 17(1):29-39. PubMed ID: 27349451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
    Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
    Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preface.
    Prudhomme M
    Anticancer Agents Med Chem; 2017; 17(1):3. PubMed ID: 28143384
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of Arene Ruthenium Antitumor Complexes.
    Su W; Tang Z; Li P
    Mini Rev Med Chem; 2016; 16(10):787-95. PubMed ID: 27161008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M; Hartinger CG
    Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strained ruthenium complexes are potent light-activated anticancer agents.
    Howerton BS; Heidary DK; Glazer EC
    J Am Chem Soc; 2012 May; 134(20):8324-7. PubMed ID: 22553960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy.
    Liu J; Lai H; Xiong Z; Chen B; Chen T
    Chem Commun (Camb); 2019 Aug; 55(67):9904-9914. PubMed ID: 31360938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.
    Notaro A; Gasser G
    Chem Soc Rev; 2017 Nov; 46(23):7317-7337. PubMed ID: 29027562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
    Kenny RG; Marmion CJ
    Chem Rev; 2019 Jan; 119(2):1058-1137. PubMed ID: 30640441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of aromaticity on anticancer activity of polypyridyl ruthenium(II) complexes: synthesis, structure, DNA/protein binding, lipophilicity and anticancer activity.
    Čanović P; Simović AR; Radisavljević S; Bratsos I; Demitri N; Mitrović M; Zelen I; Bugarčić ŽD
    J Biol Inorg Chem; 2017 Oct; 22(7):1007-1028. PubMed ID: 28695374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metal Complexes in Cancer Treatment: Journey So Far.
    Kumar Singh A; Kumar A; Singh H; Sonawane P; Pathak P; Grishina M; Pal Yadav J; Verma A; Kumar P
    Chem Biodivers; 2023 Apr; 20(4):e202300061. PubMed ID: 36824028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of Ruthenium Complexes Activities on Breast Cancer Cells.
    Popolin CP; Cominetti MR
    Mini Rev Med Chem; 2017; 17(15):1435-1441. PubMed ID: 28176627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
    Nardon C; Brustolin L; Fregona D
    Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents.
    Pal M; Nandi U; Mukherjee D
    Eur J Med Chem; 2018 Apr; 150():419-445. PubMed ID: 29547831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.